Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04475432 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
A Phase 2 study, sponsored by Tarsus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 421
- Enrollment target
NCT04475432 is a Phase 2 study that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 421 participants.
The verdict
NCT04475432, a Phase 2 study, has completed, sponsored by Tarsus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 421 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles. The hypothesis for the study is the proportion of participants cured at Day 43 with treatment by TP-03, 0.25%, is greater than the proportion cured by treatment with its vehicle.
Interventions
- DRUG TP-03 Vehicle
- DRUG TP-03, 0.25%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2021-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04475432
The ClinicalTrials.gov registry entry for NCT04475432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tarsus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TP-03 Vehicle is the first listed.
NCT04475432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04475432 about?
NCT04475432 is a clinical study titled "Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis". The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles. The hypothesis for the study is the proportion of participants cured at Da...
What is the current status of trial NCT04475432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 421 participants. The study started on 2020-09-09. Estimated completion is 2021-05-04.
What interventions are being tested in trial NCT04475432?
The interventions under investigation include: TP-03 Vehicle (DRUG), TP-03, 0.25% (DRUG).
Who is sponsoring clinical trial NCT04475432?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.